Long-term results of CCG 5942: A randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma - A report from the Children's Oncology Group Journal Article


Authors: Wolden, S. L.; Chen, L.; Kelly, K. M.; Herzog, P.; Gilchrist, G. S.; Thomson, J.; Sposto, R.; Kadin, M. E.; Hutchinson, R. J.; Nachman, J.
Article Title: Long-term results of CCG 5942: A randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma - A report from the Children's Oncology Group
Abstract: Purpose: In 1995, the Children's Cancer Group (CCG) opened a trial for patients with Hodgkin's lymphoma evaluating whether low-dose involved-field radiation therapy (IFRT) improved event-free survival (EFS) for patients achieving a complete response after chemotherapy. We present the long-term study outcome using final data through March 2007. Patients and Methods: Between January 1995 and December 1998, 826 eligible patients were enrolled onto CCG 5942. Four hundred ninety-eight patients achieving an initial complete response to chemotherapy were randomly assigned to receive IFRT or no further therapy. EFS and overall survival (OS) were assessed from the date of study entry or random assignment, as appropriate. Results: Ten-year EFS and OS rates for the entire cohort were 83.5% and 92.5%, respectively. In an as-treated analysis for randomly assigned patients, the 10-year EFS and OS rates were 91.2% and 97.1%, respectively, for IFRT and 82.9% and 95.9%, respectively, for no further therapy. For EFS and OS comparisons, P = .004 and P = .50, respectively. Bulk disease, "B" symptoms, and nodular sclerosis histology were risk factors for inferior EFS. Conclusion: With a median follow-up of 7.7 years, IFRT produced a statistically significant improvement in EFS but no improvement in OS. For individual patients, the relative risks of relapse versus late effects of IFRT must be considered. Patient and disease characteristics and early response assessment will aid in deciding which patients are most likely to benefit from IFRT. © 2012 by American Society of Clinical Oncology.
Keywords: child; controlled study; event free survival; treatment outcome; treatment response; child, preschool; disease-free survival; survival analysis; major clinical study; overall survival; prednisone; histopathology; doxorubicin; cancer combination chemotherapy; drug efficacy; drug safety; treatment duration; cancer patient; cancer radiotherapy; radiation dose; combined modality therapy; cytarabine; drug megadose; follow up; antineoplastic agent; multiple cycle treatment; etoposide; randomized controlled trial; antineoplastic combined chemotherapy protocols; clinical assessment; cohort analysis; cyclophosphamide; vincristine; risk factor; procarbazine; vinblastine; hodgkin disease; drug fatality; lung metastasis; symptom; disease severity; long term care; bleomycin; nodular sclerosis hodgkin lymphoma; gallium; secondary leukemia
Journal Title: Journal of Clinical Oncology
Volume: 30
Issue: 26
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2012-09-10
Start Page: 3174
End Page: 3180
Language: English
DOI: 10.1200/jco.2011.41.1819
PROVIDER: scopus
PMCID: PMC3434976
PUBMED: 22649136
DOI/URL:
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 2 November 2012" - "CODEN: JCOND" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Suzanne L Wolden
    419 Wolden